Claims

1. A bladder cancer ~~protein~~ biomarker, wherein the biomarker is at least three selected from the group consisting of Coronin-1A, Apolipoprotein A-IV, Semenogelin-2, Gamma-synuclein and DJ-1, and variants thereof.

2. The bladder cancer biomarker of claim 1, wherein the biomarker is indicative for early stage (Ta/T1) and/or late stage (T2/T3) bladder cancer.

3. The bladder cancer biomarker of any one of the preceding claims, wherein the biomarker is to be detected in a sample.

4. The bladder cancer biomarker of claim 3, wherein the sample is a fluid sample.

5. The bladder cancer biomarker of claim 4, wherein the fluid sample is urine or voided urine.

6. The bladder cancer biomarker of any one of the preceding claims, wherein the biomarkers consist of Coronin-1A, Apolipoprotein A-IV, Semenogelin-2, Gamma-synuclein and DJ-1.

7. A detection system comprising a) a receiving section to receive a sample from a patient suspected to suffer from bladder cancer and wherein the sample is suspected to comprise one or more biomarkers according to any one of claims 1 to 6 and b) a detection section comprising a substance or substances capable of detecting the biomarkers according to any one of claims 1 to 6.

8. The detection system of claim 7, wherein the detection section comprises a substance capable of binding or specifically binding to the biomarkers according to any one of claims 1 to 6.

9. The detection system of claim 8, wherein the substance is a biospecific capture reagent selected from the group consisting of antibodies or antigen-binding fragment thereof, interacting fusion protiens, aptamers and Affibodies.

10. The detection system of any of claims 7 to 9, wherein the system is a biochip or test strip or microtiter plate.

11. The detection system of any of claims 7 to 10, wherein the sample is a fluid sample.

12. A method of determining whether a patient suffers from or shows recurrence of bladder cancer or early stage bladder cancer or late stage bladder cancer, wherein the method comprises detecting the presence of the biomarkers according to any one of claims 1 to 6.

13. The method of claim 12, wherein the biomarkers are detected from a sample.

14. The method of claim 13, wherein the sample is a fluid sample.

15. The method of claim 14, wherein the fluid sample is urine or voided urine.

16. The method of any of claims 12 to 15, wherein detection is carried out using molecular biological methods.

17. The method of claim 16, wherein the molecular biological methods are selected from the group consisting of polymerase chain reaction (PCR), Western Blot, dot blot, mass spectrometry and immunological methods.

18. The method of any one of claims 12 to 17, wherein the method measures RNA expression.

19. The method of any one of claims 12 to 17, wherein the method measures protein expression.

~~18.~~20. The method of any one of claims 12 to ~~17~~19, wherein the indication as to whether the biomarkers are comprised in a sample obtained from the patient is made based on comparison of the results with a control group.

~~19.~~21. The method of claim ~~18~~20, wherein the control group comprises patients which do not suffer from bladder cancer.

~~20.~~22. The method of any one of claims 12 to ~~19~~21 wherein the method uses a detection system according to any one of claims 7 to 11.

~~21.~~23. A kit comprising a detection system according to any one of claims 7 to 11 and substances needed to carry out the method according to any one of claims 12 to ~~20~~22.